Specific chemotherapy of Chagas disease: controversies and advances
Tóm tắt
Từ khóa
Tài liệu tham khảo
Morel, 2000, Reaching maturity – 25 Years of the TDR, Parasitol. Today, 16, 522, 10.1016/S0169-4758(00)01815-9
Schmuñis, 2000, A Tripanossomı́ase Americana e seu impacto na suúde publica das Américas, 1
2002, Control of Chagas Disease, Tech. Rep. Ser., 905, 1
Vinhaes, 2003, Trypanosomiasis control: surmounting diminishing returns, Trends Parasitol., 19, 112, 10.1016/S1471-4922(03)00020-5
Brener, 1997, Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease, Int. Arch. Allergy Immunol., 114, 103, 10.1159/000237653
Kirchhoff, 1999, Chagas disease (American Trypanosomiasis): a tropical disease now emerging in the United States, 111
Tarleton, 1999, Chagas disease ethiology: Autoimmunity or parasite persistence?, Parasitol. Today, 15, 94, 10.1016/S0169-4758(99)01398-8
Tarleton, 2001, Parasite persistence in the aetiology of Chagas disease, Int. J. Parasitol., 31, 550, 10.1016/S0020-7519(01)00158-8
Luquetti, 1997, Etiological treatment of Chagas disease. The National Health Foundation of Brazil, Parasitol. Today, 13, 127, 10.1016/S0169-4758(97)01018-1
1998, Etiological treatment of Chagas disease, Rev. Pat. Trop., 28, 247
Docampo, 1990, Sensitivity of parasites to free radical damage by antiparasitic drugs, Chem. Biol. Interact., 73, 1, 10.1016/0009-2797(90)90106-W
Cançado, 1999, Criteria of Chagas disease cure, Mem. Inst. Oswaldo Cruz, 94, 331, 10.1590/S0074-02761999000700064
Andrade, 1992, Specific chemotherapy of Chagas' disease: a comparison between the response in patients and experimental animals infected with the same strains, Trans. R. Soc. Trop. Med. Hyg., 86, 624, 10.1016/0035-9203(92)90156-7
Bahia-Oliveira, 2000, Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14–30 years ago, J. Infect. Dis., 182, 634, 10.1086/315743
Romanha, 2002, Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitological cure, J. Infect. Dis., 186, 823, 10.1086/342415
de Andrade, 1996, Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection, Lancet, 348, 1407, 10.1016/S0140-6736(96)04128-1
Sosa Estani, 1998, Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease, Am. J. Trop. Med. Hyg., 59, 526, 10.4269/ajtmh.1998.59.526
Sosa Estani, 1999, Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines in Argentina, Mem. Inst. Oswaldo Cruz, 94, 363, 10.1590/S0074-02761999000700070
Silveira, 2000, Avaliação do tratamiento especifico para o Trypanosoma cruzi en criaças, na evolucion da fase indeterminada, Rev. Soc. Bras. Med. Trop., 33, 191, 10.1590/S0037-86822000000200006
Solari, 2001, Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3-year follow-up study, J. Antimicrob. Chemother., 48, 515, 10.1093/jac/48.4.515
Añez, 1999, Myocardial parasite persistence in chronic chagasic patients, Am. J. Trop. Med. Hyg., 60, 726, 10.4269/ajtmh.1999.60.726
Braga, 2000, Persistent infections in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives, Rev. Inst. Med. Trop. Sao Paulo, 42, 157, 10.1590/S0036-46652000000300009
Britto, 2001, Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction, Mem. Inst. Oswaldo Cruz, 96, 823, 10.1590/S0074-02762001000600014
Lauria-Pires, 2000, Progressive chronic Chagas disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives, Am. J. Trop. Med. Hyg., 63, 111, 10.4269/ajtmh.2000.63.111
Urbina, 2001, Specific treatment of Chagas disease: current status and new developments, Curr. Opin. Infect. Dis., 14, 733, 10.1097/00001432-200112000-00012
Viotti, 1994, Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up, Am. Heart J., 127, 151, 10.1016/0002-8703(94)90521-5
Docampo, 2001, Recent developments in the chemotherapy of Chagas' disease, Curr. Pharm. Des., 7, 1157, 10.2174/1381612013397546
Coura, 2002, A critical review on Chagas disease chemotherapy, Mem. Inst. Oswaldo Cruz, 97, 3, 10.1590/S0074-02762002000100001
Apt, 1998, Treatment of chronic Chagas' disease with itraconazole and allopurinol, Am. J. Trop. Med. Hyg., 59, 133, 10.4269/ajtmh.1998.59.133
Apt, 2003, Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up, Ann. Trop. Med. Parasitol., 97, 23, 10.1179/000349803125002751
Urbina, 2003, Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains, Int. J. Antimicrob. Agents, 21, 39, 10.1016/S0924-8579(02)00274-1
Urbina, 2003, In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease, Int. J. Antimicrob. Agents, 21, 27, 10.1016/S0924-8579(02)00273-X
Urbina, 2000, In vitro antiproliferative effects and mechanism of action of the new triazole derivative ur-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, Antimicrob. Agents Chemother., 44, 2498, 10.1128/AAC.44.9.2498-2502.2000
Buckner, 2001, Potent anti-Trypanosma cruzi activities of oxidosqualene cyclase inhibitors, Antimicrob. Agents Chemother., 45, 1210, 10.1128/AAC.45.4.1210-1215.2001
Urbina, 2002, Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana, Mol. Biochem. Parasitol., 125, 35, 10.1016/S0166-6851(02)00206-2
Urbina, 2003, New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis), Expert Opin. Ther. Pat., 13, 661, 10.1517/13543776.13.5.661
Cazzulo, 2001, The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease, Curr. Pharm. Des., 7, 1143, 10.2174/1381612013397528
Caffrey, 2000, Cysteine proteinases of Trypanosoma parasites: novel targets for chemotherapy, Curr. Drug Targets, 1, 155, 10.2174/1389450003349290
Engel, 1998, Cysteine protease inhibitors cure experimental Trypanosma cruzi infection, J. Exp. Med., 188, 725, 10.1084/jem.188.4.725
Du, 2002, Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain, J. Med. Chem., 45, 2695, 10.1021/jm010459j
Rodan, 2000, Therapeutic approaches to bone diseases, Science, 289, 1508, 10.1126/science.289.5484.1508
Montalvetti, 2001, Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase, J. Biol. Chem., 276, 33930, 10.1074/jbc.M103950200
Docampo, 2001, Bisphosphonates as chemotherapeutic agents against Trypanosomatid and Apicomplexan parasites, Curr. Drug Targets Infect. Disord., 1, 51, 10.2174/1568005013343191
Stoppani, 1999, Quimioterapia de la Enfermedad de Chagas, Medicina, 59, 147
Lauria-Pires, 1988, Ineffectiveness of allopurinol in patients in the acute phase of Chagas disease, Rev. Soc. Bras. Med. Trop., 21, 79, 10.1590/S0037-86821988000200011
World Health Organization (1995) Tropical disease research. In Twelfth Programme Report, UNDP/World Bank/World Health Organization Programme for Research and Training in Tropical Diseases, pp. 129–133, World Health Organization.
Freymann, 2000, Efficient incorporation of inhibitors targeting the closed active site conformation of HPRT from Trypanosoma cruzi, Chem. Biol., 7, 957, 10.1016/S1074-5521(00)00045-4
Schmidt, 2002, Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development, Curr. Top. Med. Chem., 2, 1239, 10.2174/1568026023393048
Gilbert, 2002, Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes, Biochim. Biophys. Acta, 587, 249, 10.1016/S0925-4439(02)00088-1
Saraiva, 2002, Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi, Antimicrob. Agents Chemother., 46, 3472, 10.1128/AAC.46.11.3472-3477.2002
Gelb, 2003, Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics, Mol. Biochem. Parasitol., 126, 155, 10.1016/S0166-6851(02)00282-7
Kalil, 1996, Autoimmunity in Chagas disease cardiomyopathy: fullfilling the criteria at last?, Parasitol. Today, 12, 396, 10.1016/0169-4758(96)10058-2
Engman, 2002, Pathogenesis of Chagas heart disease: role of autoimmunity, Acta Trop., 81, 123, 10.1016/S0001-706X(01)00202-9
Urbina, 1999, Parasitological cure of Chagas Disease: is it possible? Is it relevant?, Mem. Inst. Oswaldo Cruz, 94, 349, 10.1590/S0074-02761999000700068